• Explore /
  • Poster
  • / Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

Abstract Video & Slides Poster

Authors

null

Lin Shen

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, Haidian District, China

Lin Shen , Dan Liu , Ning Li , Weijian Guo , Tianshu Liu , Hongli Li , Jiayi Li , Yuxian Bai , Yanhong Deng , Zhi-xiang Zhuang , Meili Sun , Qingxia Fan , Fuyou Zhao , Liang Han , Zhenzhong Xia , Jianming Wang , Charlie Qi , Li Xu , Xueming Qian , Caroline Germa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04495296

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4046)

DOI

10.1200/JCO.2023.41.16_suppl.4046

Abstract #

4046

Poster Bd #

367

Abstract Disclosures

Similar Posters

First Author: Ke-Feng Ding

First Author: Yue Liu

First Author: Sun Young Rha

First Author: Ning Li